At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of the breast
- ✓Postmenopausal status
- ✓Stage IV disease or inoperable locally advanced disease (stage IIIB/IIIC)
- ✓ER- and/or PR-positive disease
- ✕Prior chemotherapy for metastatic disease
- ✕Radiotherapy within 4 weeks prior to enrollment
- ✕Two or more prior doses of fulvestrant
- ✕Rapidly progressive, life-threatening metastases including extensive hepatic involvement (>50% liver), symptomatic lymphangitic metastases, or brain/leptomeningeal involvement
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating fulvestrant and tipifarnib for Estrogen Receptor-positive Breast Cancer and 4 related conditions. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving tipifarnib together with fulvestrant works as second-line therapy in treating postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast cancer that has progressed after previous first-line endocrine therapy. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen. Combining tipifarnib with fulvestrant may kill tumor cells that did not respond to first-line therapy.
Study Details
Timeline
Interventions
Given intramuscularly
Given IV